Commerzbank Aktiengesellschaft FI Has $7.33 Million Stock Position in CVS Health Corporation $CVS

Commerzbank Aktiengesellschaft FI raised its stake in CVS Health Corporation (NYSE:CVS) by 87.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 102,099 shares of the pharmacy operator’s stock after buying an additional 47,646 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in CVS Health were worth $7,333,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sei Investments Co. raised its stake in shares of CVS Health by 17.4% in the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after purchasing an additional 134,535 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after buying an additional 13,329 shares during the period. Treasurer of the State of North Carolina grew its holdings in shares of CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after buying an additional 7,588 shares in the last quarter. HUB Investment Partners LLC raised its position in CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after buying an additional 3,011 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after acquiring an additional 119,439 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analysts Set New Price Targets

CVS has been the subject of a number of recent research reports. Argus upped their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. Royal Bank Of Canada lifted their price objective on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, July 9th. Sanford C. Bernstein increased their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Mizuho raised their target price on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Finally, JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Twenty-one research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $105.38.

Insider Transactions at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,441,551 shares of company stock worth $323,703,977 over the last quarter. Corporate insiders own 0.85% of the company’s stock.

CVS Health Stock Up 0.0%

CVS stock opened at $107.49 on Tuesday. The company has a market cap of $137.15 billion, a price-to-earnings ratio of 47.35, a P/E/G ratio of 1.05 and a beta of 0.61. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $108.97. The business has a 50 day moving average price of $99.28 and a two-hundred day moving average price of $85.36. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts anticipate that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be given a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.5%. CVS Health’s dividend payout ratio is currently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.